National Institute on Alcohol Abuse and Alcoholism, Notice of Closed Meetings, 52451-52452 [2016-18688]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
including Freedom of Information Act
requests.
Office of the Associate Administrator
(RV)
mstockstill on DSK3G9T082PROD with NOTICES
Administrative Operations (RV21);
replace in their entirety.
Office of Operations and Management
(RV2)
The Office of Operations and
Management provides expertise
guidance, leadership, and support in the
areas of general administration, fiscal
operations, and contract administration.
The Office of Operations and
Management is responsible for
providing direction on all budgetary,
administrative, human resources,
operations, facility management and
contracting functions for the HIV/AIDS
Bureau. The Office also oversees and
coordinates all Bureau program integrity
activities.
The Office of the Associate
Administrator provides leadership and
direction for the HIV/AIDS programs
and activities of the Bureau and
oversees its relationship with other
national health programs. Specifically:
(1) promotes the implementation of the
National HIV/AIDS Strategy within the
Agency and among Agency-funded
programs; (2) coordinates the
formulation of an overall strategy and
policy for programs established by Title
XXVI of the PHS Act as amended by the
Ryan White HIV/AIDS Treatment
Extension Act of 2009, P.L. 111–87; (3)
coordinates the internal functions of the
Bureau and its relationships with other
Agency Bureaus and Offices; (4)
establishes HIV/AIDS program
objectives, alternatives, and policy
positions consistent with broad
Administration guidelines; (5) provides
leadership for and oversight of the
Bureau’s budgetary development and
implementation processes; (6) provides
clinical leadership to Ryan Whitefunded programs and global HIV/AIDS
programs; (7) oversees the
implementation of the Global HIV/AIDS
Program as part of the President’s
Emergency Plan for AIDS Relief; (8)
serves as a principal contact and advisor
to the Department and other parties on
matters pertaining to the planning and
development of HIV/AIDS-related
health delivery systems; (9) reviews
HIV/AIDS related program activities to
determine their consistency with
established policies; (10) develops and
oversees operating policies and
procedures for the Bureau; (11) oversees
and directs the planning,
implementation, and evaluation of
special studies related to HIV/AIDS and
public health within the Bureau; (12)
prioritizes technical assistance needs in
consultation with each division/office;
(13) plans, implements, and evaluates
the Bureau’s national technical
assistance resource training center Web
site and other distance learning
modalities; (14) represents the Agency
in HIV/AIDS related conferences,
consultations, and meetings with other
Operating Divisions, Office of the
Assistant Secretary for Health, the
Department of State, and the White
House; and (15) oversees Bureau
Executive Secretariat functions and
coordinates HRSA responses and
comments on HIV/AIDS-related reports,
position papers, guidance documents,
correspondence, and related issues,
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
Division of Administrative Operations
(RV21)
The Division of Administrative
Operations is responsible for the
administrative, human resources
operations, facility management and
contracting functions for the Bureau.
Specifically, these functions are carried
out in the Administrative Services and
Contracting Services Team.
Office of Program Support (RV3)
The Office of Program Support
provides expertise, guidance,
leadership, and support in the areas of
organizational development,
communications, grantee oversight, and
customer service to support program
implementation. Specifically, the Office
of Program Support: (1) enhances the
coordination of program support, grants
management, and technical assistance
across the entire Bureau; (2) plans,
implements and evaluates HAB staff
development and education to enable
employees to meet the mission of the
Bureau; (3) streamlines
communications, clearance activities
and development of consistent, quality
presentations; (4) improves the Bureau’s
external facing communication efforts;
(5) facilitates transparency in sharing
the Bureau’s data using internal and
external resources; (6) provides
leadership for and oversees Bureau’s
grants processes; (7) coordinates the
grants liaison activities; (8) supports
grantee oversight and improves
customer service and technical
assistance to grantees; (9) serves as the
Bureau’s primary liaison with the Office
of Federal Assistance Management; (10)
supports systems development to
improve program efficiencies and
management; (11) provides support with
the implementation of staff
development, organizational
development and training activities; (12)
plans, develops, implements and
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
52451
evaluates the Bureau’s organizational
and staff development, and staff training
activities inclusive of guiding action
steps addressing annual Employee
Viewpoint Survey results; and (13)
coordinates the development and
distribution of all Bureau
communication activities, materials and
products internally and externally.
Delegations of Authority
All delegations of authority and redelegations of authority made to HRSA
officials that were in effect immediately
prior to this reorganization, and that are
consistent with this reorganization,
shall continue in effect pending further
re-delegation.
This reorganization is effective upon
date of signature.
Dated: August 1, 2016.
James Macrae,
Acting Administrator.
[FR Doc. 2016–18730 Filed 8–5–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism, Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group; Biomedical Research Review
Subcommittee.
Date: October 18, 2016.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Alcohol Abuse
and Alcoholism, National Institutes of
Health, Conference Room 3002–3004, 5635
Fishers Lane, Rockville, MD 20852.
Contact Person: Philippe Marmillot, Ph.D.,
Scientific Review Officer, National Institute
on Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Room
E:\FR\FM\08AUN1.SGM
08AUN1
52452
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
2019, Bethesda, MD 20892, 301–443–2861,
marmillotp@mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group; Neuroscience Review
Subcommittee.
Date: October 27, 2016.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Alcohol Abuse
and Alcoholism, National Institutes of
Health, Terrace Level Conference Room 508–
509, 5635 Fishers Lane, Rockville, MD 20852.
Contact Person: Beata Buzas, Ph.D.,
Scientific Review Officer, National Institute
On Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm.
2081, Rockville, MD 20852, 301–443–0800,
bbuzas@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–18688 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and co-
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
development research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Synthetic HumanDerived Peptides and Peptidomimetics
for Cancer Therapeutics
Keywords: Rpn13, selective
proteasome inhibitor, proteasome
ubiquitin receptors, (competition:
carfilzomib and bortezomib too toxic,
resistance developed), solid tumors,
hematological cancer, HPV associated
cancer, ovarian cancer, prostate cancer,
gastric cancer, breast cancer, or
colorectal cancer
Description of Technology: FDA
approved 26S proteasome inhibitors,
such as carfilzomib and bortezomib
(Velcade®) have proven to be effective at
treating hematologic cancers. However,
resistance to these agents as well as
their toxicity have raised concerns and
highlight the need for new 26S
proteasome inhibitors.
Investigators at the NCI’s Structural
Biophysics Laboratory have developed a
new class of proteasome inhibitors.
They are hRpn2-derived peptides
capable of specifically targeting the Pru
domain of hRpn13. Disruption of the
Rpn2/Rpn13 interaction inhibits
proteolysis by a mechanism that differs
from those of the approved proteasome
inhibitors.
Potential Commercial Applications:
• New class of proteasome inhibitors,
targeting hRpn13 of the regulatory
particle.
Value Proposition:
• Synergistic with, and more specific
than, known proteasome inhibitors.
• Alternate mechanism of action
compared to approved proteasome
inhibitors.
Development Stage: Discovery (Lead
ID).
Inventor(s): Kylie J. Walters (NCI), Fen
Liu (NCI), and Xiuxiu Lu (NCI).
Intellectual Property:
HHS Reference No. E–278–2015/0–
US–01.
US Provisional Application 62/
222,530 (HHS Reference No. E–278–
2015) filed September 23, 2015 entitled
‘‘Human RPN2 Derived Peptides Useful
For Treating Cancer’’.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Publications: 1. Lu X., et al., 2015
PLoS One 2015 Oct 14;10(10) PMID:
26466095.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: July 26, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–18689 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App. 2), notice is
hereby given of the meeting of the
National Cancer Advisory Board
(NCAB).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Open: September 7, 2016, 9:00 a.m. to
05:00 p.m.
Agenda: Programs reports and
presentations; business of the Board.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Closed: September 7, 2016, 04:00 p.m. to
05:00 p.m.
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Pages 52451-52452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18688]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism, Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Initial Review Group; Biomedical Research Review
Subcommittee.
Date: October 18, 2016.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Alcohol Abuse and Alcoholism,
National Institutes of Health, Conference Room 3002-3004, 5635
Fishers Lane, Rockville, MD 20852.
Contact Person: Philippe Marmillot, Ph.D., Scientific Review
Officer, National Institute on Alcohol Abuse and Alcoholism,
National Institutes of Health, 5635 Fishers Lane, Room
[[Page 52452]]
2019, Bethesda, MD 20892, 301-443-2861, marmillotp@mail.nih.gov.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Initial Review Group; Neuroscience Review Subcommittee.
Date: October 27, 2016.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Alcohol Abuse and Alcoholism,
National Institutes of Health, Terrace Level Conference Room 508-
509, 5635 Fishers Lane, Rockville, MD 20852.
Contact Person: Beata Buzas, Ph.D., Scientific Review Officer,
National Institute On Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm. 2081, Rockville, MD
20852, 301-443-0800, bbuzas@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.271,
Alcohol Research Career Development Awards for Scientists and
Clinicians; 93.272, Alcohol National Research Service Awards for
Research Training; 93.273, Alcohol Research Programs; 93.891,
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical
Research and Research Support Awards, National Institutes of Health,
HHS)
Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-18688 Filed 8-5-16; 8:45 am]
BILLING CODE 4140-01-P
